Gliclize 40/60/80 mg MR Tablets – Uses, Benefits and Side Effects

Gliclize 40 mg, 60 mg and 80 mg MR Tablets are oral medicine products associated with the management of type 2 diabetes. Before publishing product specifications, confirm the active ingredient and whether each strength is available in a modified-release (MR) formulation from the approved product packaging.

Gliclazide is a sulfonylurea antidiabetic medicine that helps lower blood glucose by stimulating insulin release from the pancreas. It is prescribed for eligible adults with type 2 diabetes when diet, exercise and other measures alone are insufficient to control blood sugar.

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information and handles product supply enquiries. Buyers can contact the company to confirm available strengths, manufacturer details, packaging, documentation, applicable export requirements and destination-country availability.

Uses and Benefits of Gliclize MR Tablets

When the confirmed active ingredient is gliclazide, its principal use is the management of type 2 diabetes under medical supervision.

Potential treatment benefits include:

Blood glucose management: Helps reduce elevated blood glucose levels when used as prescribed.

Support for diabetes care: May be used alongside a suitable diet, regular physical activity and routine glucose monitoring.

Individualised treatment: The prescribed strength and formulation can be selected according to the patient's glucose control, response and clinical circumstances.

Long-term management: Appropriate diabetes treatment may help reduce the risk of complications associated with persistently elevated blood glucose.

These benefits depend on correct diagnosis, adherence to treatment and regular medical follow-up. The medicine is not intended to treat type 1 diabetes or diabetic ketoacidosis.

Side Effects of Gliclazide Tablets

Gliclazide may cause side effects, although not everyone experiences them. The most important risk is hypoglycaemia (low blood sugar).

Possible side effects include:

Headache, dizziness or weakness

Nausea, stomach discomfort or diarrhoea

Increased hunger, sweating or trembling

Palpitations or difficulty concentrating

Skin rash or itching

Severe hypoglycaemia can cause confusion, seizures or loss of consciousness and requires urgent medical attention. Seek immediate help for severe symptoms or a serious allergic reaction.

Patients should take the medicine exactly as prescribed and avoid skipping meals. Alcohol, irregular eating, strenuous activity and other diabetes medicines may increase the risk of low blood sugar. Inform the doctor about other medicines, kidney or liver problems, pregnancy or breastfeeding before treatment.

Frequently Asked Questions

1. What are Gliclize 40/60/80 mg MR Tablets used for?

If the product contains gliclazide, it is used to help manage blood glucose in adults with type 2 diabetes.

2. What does MR mean in a tablet?

MR generally means modified release, a formulation designed to release medicine over a specified period. Always follow the instructions for the exact product.

3. Can these tablets be taken daily?

The frequency depends on the verified formulation and the prescriber's instructions. Do not change the dose or schedule independently.

4. What should I do if my blood sugar becomes low?

Follow your clinician's hypoglycaemia plan. If conscious and able to swallow, take fast-acting glucose or sugar as advised. Severe symptoms, seizures or unconsciousness require emergency assistance; do not give food or drink to an unconscious person.

5. How can buyers enquire about this product?

Contact Cordium Pharmaceuticals Pvt Ltd to confirm the product's active ingredient, available strengths, packaging, supply terms and destination-market requirements. Supply is subject to applicable laws and regulatory approvals.

Important Medical Disclaimer: This content is for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Product details must be verified against the approved package insert before publication or use.